2026 Interim Report
Filed with HKEX · Stock code 2179 · · 102 pages · English and Chinese
Summary by 6ix AI
It includes financial highlights, management discussion, and analysis of the company's performance and operations. The report outlines the company's focus on innovative vaccine development and its current projects in clinical trials. It also details the company's financial position, including total assets and liabilities as of the reporting date.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Jiangsu Recbio Technology Co., Ltd. on 6ix
Earlier from Jiangsu Recbio Technology
- Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
- Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
- Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Later from Jiangsu Recbio Technology
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement receipt of phase III clinical trial summary report for novel adjuvanted recombinant shingles vaccine REC610
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Jiangsu Recbio Technology into a list and get an email when it puts out news.
Follow Jiangsu Recbio Technology